Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) to Enhance Immunotherapy Against T Cell Non-Hodgkin Lymphoma (NHL): a First-in-human Phase I Clinical Trial

NCT06420089 is registered in ClinicalTrials.gov with Vittoria Biotherapeutics as lead sponsor.

NCT NCT06420089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06420089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) to Enhance Immunotherapy Against T Cell Non-Hodgkin Lymphoma (NHL): a First-in-human Phase I Clinical Trial
Lead sponsor
Vittoria Biotherapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
October 4, 2024
Completion date
August 30, 2029
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

t cell non-hodgkin lymphoma